Moderna Inc (MRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Moderna Inc (MRNA) has a cash flow conversion efficiency ratio of -0.078x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-526.00 Million) by net assets ($6.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Moderna Inc stock valuation for the company's overall valuation and market capitalisation.
Moderna Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Moderna Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Moderna Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moderna Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Moderna Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sempra Energy
NYSE:SRE
|
0.042x |
|
Societe Generale S.A.
PA:GLE
|
-0.332x |
|
KDDI CORP.UNSP.ADR 4
F:DIP0
|
N/A |
|
Nu Holdings Ltd
NYSE:NU
|
0.073x |
|
Devon Energy Corporation
NYSE:DVN
|
0.108x |
|
Garmin Ltd
NYSE:GRMN
|
0.037x |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
0.217x |
|
Life Insurance Corporation Of India
NSE:LICI
|
0.034x |
Annual Cash Flow Conversion Efficiency for Moderna Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Moderna Inc from 2014 to 2025. View latest Moderna Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Billion | $-1.87 Billion | -0.217x | +21.42% |
| 2024-12-31 | $10.90 Billion | $-3.00 Billion | -0.276x | -22.44% |
| 2023-12-31 | $13.85 Billion | $-3.12 Billion | -0.225x | -186.41% |
| 2022-12-31 | $19.12 Billion | $4.98 Billion | 0.260x | -72.95% |
| 2021-12-31 | $14.14 Billion | $13.62 Billion | 0.963x | +21.66% |
| 2020-12-31 | $2.56 Billion | $2.03 Billion | 0.791x | +302.59% |
| 2019-12-31 | $1.17 Billion | $-458.97 Million | -0.391x | -80.69% |
| 2018-12-31 | $1.53 Billion | $-330.87 Million | -0.216x | +59.21% |
| 2017-12-31 | $625.30 Million | $-331.48 Million | -0.530x | -768.75% |
| 2016-12-31 | $841.85 Million | $66.73 Million | 0.079x | +100.97% |
| 2015-12-31 | $90.19K | $-738.15K | -8.185x | -848.61% |
| 2014-12-31 | $-4.37 Million | $-4.78 Million | 1.093x | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more